BR112019018863A8 - Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos - Google Patents

Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos

Info

Publication number
BR112019018863A8
BR112019018863A8 BR112019018863A BR112019018863A BR112019018863A8 BR 112019018863 A8 BR112019018863 A8 BR 112019018863A8 BR 112019018863 A BR112019018863 A BR 112019018863A BR 112019018863 A BR112019018863 A BR 112019018863A BR 112019018863 A8 BR112019018863 A8 BR 112019018863A8
Authority
BR
Brazil
Prior art keywords
high affinity
mage
specific high
tcrs
affinity tcrs
Prior art date
Application number
BR112019018863A
Other languages
English (en)
Other versions
BR112019018863A2 (pt
Inventor
Chapuis Aude
Schmitt Thomas
McAfee Megan
Original Assignee
Hutchinson Fred Cancer Res
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res, Fred Hutchinson Cancer Center filed Critical Hutchinson Fred Cancer Res
Publication of BR112019018863A2 publication Critical patent/BR112019018863A2/pt
Publication of BR112019018863A8 publication Critical patent/BR112019018863A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

A presente divulgação fornece TCRs com alta afinidade ou com afinidade aprimorada contra vários antígenos associados a tumores (incluindo epítopos de MAGE-A1 humano), células T que expressam esses TCRs de alta afinidade antígenos-específicos, ácidos nucleicos que codificam os mesmos e composições para uso no tratamento de doenças ou distúrbios em que as células superexpressam um ou mais desses antígenos, como no câncer.
BR112019018863A 2017-03-15 2018-03-15 Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos BR112019018863A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471956P 2017-03-15 2017-03-15
PCT/US2018/022759 WO2018170338A2 (en) 2017-03-15 2018-03-15 High affinity mage-a1-specific tcrs and uses thereof

Publications (2)

Publication Number Publication Date
BR112019018863A2 BR112019018863A2 (pt) 2020-04-14
BR112019018863A8 true BR112019018863A8 (pt) 2023-05-02

Family

ID=63523985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018863A BR112019018863A8 (pt) 2017-03-15 2018-03-15 Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos

Country Status (13)

Country Link
US (2) US11034748B2 (pt)
EP (1) EP3595708A4 (pt)
JP (2) JP7037577B2 (pt)
KR (1) KR102375033B1 (pt)
CN (1) CN110582299A (pt)
AU (1) AU2018234830B2 (pt)
BR (1) BR112019018863A8 (pt)
CA (1) CA3055983A1 (pt)
EA (1) EA201992131A1 (pt)
IL (1) IL269250A (pt)
MX (1) MX2019010972A (pt)
SG (1) SG11201908527SA (pt)
WO (1) WO2018170338A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916092T3 (es) 2016-12-08 2022-06-28 Immatics Biotechnologies Gmbh Nuevos receptores de linfocitos T e inmunoterapias basadas en el uso de los mismos
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
EP3595708A4 (en) * 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGHLY POTENTIAL MAGE-A1 SPECIFIC TCRS AND USES
CN112188895A (zh) * 2018-04-19 2021-01-05 贝勒医学院 通过强制表达CD8αβ和1类限制性T细胞受体将CD4 T细胞重编程为细胞毒性CD8细胞
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
TW202102530A (zh) 2019-04-04 2021-01-16 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
CN113748127A (zh) * 2019-05-01 2021-12-03 派克特制药公司 使用cd8改造的t细胞疗法治疗癌症的组合物和方法
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
CN111320703A (zh) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 靶向cd22的嵌合抗原受体及其应用
CN111499763A (zh) * 2020-03-31 2020-08-07 江苏省省级机关医院 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
WO2022076353A1 (en) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions and methods for treating mage-a1-expressing disease
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4259651A2 (en) 2020-12-14 2023-10-18 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
WO2023083864A1 (en) 2021-11-09 2023-05-19 T-Knife Gmbh Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
CN116063458A (zh) * 2022-04-27 2023-05-05 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
WO2023232111A1 (zh) * 2022-06-01 2023-12-07 北京可瑞生物科技有限公司 Mage-a1特异性tcr及其用途
NL2032130B1 (en) 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
CA2626262C (en) 2005-10-18 2015-09-08 Homme W. Hellinga Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
US20080064631A1 (en) * 2006-01-13 2008-03-13 Jeffrey Molldrem T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease
CA2700436C (en) * 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
WO2008108257A1 (ja) * 2007-03-05 2008-09-12 International Institute Of Cancer Immunology, Inc. 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
US8785601B2 (en) * 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
CA2798988C (en) 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
ME02810B (me) * 2010-09-20 2018-01-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t ćelijski receptori i t ćelijski epitopi
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
AU2012276908A1 (en) * 2011-06-28 2014-02-20 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
CN102295702B (zh) * 2011-08-26 2014-01-29 中国科学院微生物研究所 一种针对t细胞受体可变区特异性单抗的制备方法
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
EA038924B1 (ru) 2012-05-25 2021-11-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы и композиции рнк-специфической модификации днк-мишени и рнк-специфической модуляции транскрипции
AU2013305838A1 (en) 2012-08-20 2015-02-26 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2932421A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
WO2014100439A2 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
JP6639233B2 (ja) * 2013-01-29 2020-02-05 マックス−デルブリュック−セントラム フュア モレクラーレ メディツィン（エムディーシー） ベルリン−ブッフ Ｍａｇｅ−ａ１を認識する高結合活性結合分子
JP6464140B2 (ja) * 2013-03-13 2019-02-06 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
WO2015071474A2 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
AU2014352826B2 (en) * 2013-11-22 2019-08-01 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human T cell receptors
DK3514172T3 (da) * 2014-04-01 2020-04-06 Biontech Cell & Gene Therapies Gmbh Claudin-6-specifikke immunoreceptorer og t-celleepitoper
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
EP2944652A1 (en) * 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
US10538572B2 (en) * 2014-08-04 2020-01-21 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for WT-1
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
EP3193892A4 (en) * 2014-09-14 2018-09-12 Washington University Personalized cancer vaccines and methods therefor
AU2015327781A1 (en) 2014-10-03 2017-04-20 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
CN107580500B (zh) 2015-02-19 2023-05-30 康姆普根有限公司 抗pvrig抗体和使用方法
AU2016258845B2 (en) * 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CN106188274A (zh) * 2015-05-06 2016-12-07 广州市香雪制药股份有限公司 识别rhamm抗原短肽的t细胞受体
NZ737400A (en) * 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN105316362B (zh) * 2015-08-19 2020-03-17 暨南大学 一种Dual-RMCE介导的TCR基因置换***及其方法
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
JP6989138B2 (ja) * 2016-06-17 2022-01-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体及びその使用
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
EP3595708A4 (en) * 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGHLY POTENTIAL MAGE-A1 SPECIFIC TCRS AND USES

Also Published As

Publication number Publication date
AU2018234830B2 (en) 2023-03-02
BR112019018863A2 (pt) 2020-04-14
MX2019010972A (es) 2019-12-02
JP2021090462A (ja) 2021-06-17
EP3595708A4 (en) 2020-12-16
CN110582299A (zh) 2019-12-17
WO2018170338A2 (en) 2018-09-20
KR102375033B1 (ko) 2022-03-15
JP7037577B2 (ja) 2022-03-16
US11034748B2 (en) 2021-06-15
KR20190129082A (ko) 2019-11-19
AU2018234830A1 (en) 2019-09-26
IL269250A (en) 2019-11-28
CA3055983A1 (en) 2018-09-20
EA201992131A1 (ru) 2020-02-06
EP3595708A2 (en) 2020-01-22
JP2020509767A (ja) 2020-04-02
US20200017568A1 (en) 2020-01-16
WO2018170338A3 (en) 2019-11-21
US20210355189A1 (en) 2021-11-18
SG11201908527SA (en) 2019-10-30

Similar Documents

Publication Publication Date Title
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
PE20200494A1 (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
AR105600A1 (es) Anticuerpos contra la angiopoyetina implicada en metabolismo de los triglicéridos (anti-angptl8) y usos de los mismos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112016030462A2 (pt) moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
BR112018013074A2 (pt) terapias de célula efetora imune com eficácia real-çada
BR112019021822A2 (pt) Terapia de combinação
BR112017022249A2 (pt) células t gama delta modificadas e usos destas
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
BR112015020804A2 (pt) dispositivo fototerapeutico, método e uso
CO2018002568A2 (es) Acetamida tienotriazolodiazepinas y usos de las mismas
BR112018067977A2 (pt) composições e métodos para imunoterapia para cd20
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
BR112020009655A8 (pt) Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: FRED HUTCHINSON CANCER CENTER (US)